Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) shares traded down 1.3% on Wednesday . The company traded as low as $10.61 and last traded at $11.1760. 2,162 shares were traded during mid-day trading, a decline of 64% from the average daily volume of 6,077 shares. The stock had previously closed at $11.32.
Drugs Made in America Acquisition Trading Down 0.6%
The firm has a fifty day moving average of $10.76 and a 200-day moving average of $10.60.
Drugs Made in America Acquisition Company Profile
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Featured Articles
- Five stocks we like better than Drugs Made in America Acquisition
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
- Why Palantir’s Google Cloud Deal Could Change the Debate
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
